Current Portfolio

Current Portfolio



June 2016

PRIVATE: Anthro is a full service marketing and media marketplace that connects tens of millions of engaged fans to some of the the world's largest influencers in sports, entertainment and more. Anthro's media platform works with influencers, brands and fans to share exclusive content created to engage and entertain. The company's passion is creating connections from one to millions through their platform but branded to the influencers. Authentic content direct from the source has been the company's mission since day 1. Anthro gives partners the opportunity, through their platform and services, to own their content and benefit from directly connecting with their millions of fans.

LEARN MORE


October 2014

CLLS: Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets.

LEARN MORE


March 2016

ITCI: Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of several neuropsychiatric and neurodegenerative diseases. The lead compound in this platform, ITI-214, has finished several Phase 1 clinical trials and has been demonstrated to be safe and well-tolerated.  In addition, the Company is developing inhibitors against other targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as pulmonary arterial hypertension, multiple sclerosis, COPD and lung fibrosis.

LEARN MORE


March 2015

LBIO: Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TILs). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute and is currently in use at leading cancer centers in the US. Their lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of Stage 4 metastatic melanoma. In Phase 2 clinical trials, patients treated with this product demonstrated objective response rates of 49%, significantly exceeding those associated with existing melanoma treatments. In addition to metastatic melanoma, their TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers. As hey continue advancing their current clinical programs, they are also developing next-generation TILs and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost.

LEARN MORE


March 2016

RDUS: Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.

LEARN MORE


January 2015

PRIVATE: Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG.

LEARN MORE